Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by Kovack Advisors Inc.

Kovack Advisors Inc. raised its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 3.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 56,485 shares of the specialty pharmaceutical company’s stock after buying an additional 2,068 shares during the period. Kovack Advisors Inc. owned about 0.09% of Jazz Pharmaceuticals worth $5,994,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Philip James Wealth Mangement LLC lifted its position in Jazz Pharmaceuticals by 42.0% during the second quarter. Philip James Wealth Mangement LLC now owns 15,797 shares of the specialty pharmaceutical company’s stock valued at $1,676,000 after buying an additional 4,675 shares in the last quarter. State of Alaska Department of Revenue lifted its position in Jazz Pharmaceuticals by 75.1% during the second quarter. State of Alaska Department of Revenue now owns 57,933 shares of the specialty pharmaceutical company’s stock valued at $6,147,000 after buying an additional 24,850 shares in the last quarter. Inspire Investing LLC acquired a new position in Jazz Pharmaceuticals during the first quarter valued at approximately $689,000. Baird Financial Group Inc. acquired a new position in Jazz Pharmaceuticals during the first quarter valued at approximately $539,000. Finally, Voya Investment Management LLC lifted its position in Jazz Pharmaceuticals by 67.1% during the first quarter. Voya Investment Management LLC now owns 56,349 shares of the specialty pharmaceutical company’s stock valued at $6,996,000 after buying an additional 22,628 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Trading Up 0.4%

Jazz Pharmaceuticals stock opened at $136.30 on Friday. The firm’s 50-day moving average is $131.90 and its 200-day moving average is $117.88. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06. The company has a market cap of $8.27 billion, a P/E ratio of -20.25, a PEG ratio of 8.49 and a beta of 0.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The business had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter in the previous year, the business posted $5.30 earnings per share. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, equities analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Insider Activity

In other news, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total value of $771,720.00. Following the transaction, the director directly owned 429,973 shares in the company, valued at approximately $55,303,127.26. This trade represents a 1.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have sold 11,500 shares of company stock valued at $1,525,280. Company insiders own 4.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on JAZZ shares. Deutsche Bank Aktiengesellschaft started coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They set a “buy” rating and a $152.00 price target on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Jazz Pharmaceuticals in a research note on Wednesday, October 8th. JPMorgan Chase & Co. dropped their price objective on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research note on Monday. Royal Bank Of Canada lifted their price objective on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an “outperform” rating in a research note on Thursday, August 28th. Finally, Morgan Stanley set a $183.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, October 24th. Fourteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $179.33.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.